Core Viewpoint - The independent financial advisor report by Shanghai Miaodao Enterprise Management Consulting Co., Ltd. confirms that the conditions for the third vesting period of the 2022 A-share restricted stock incentive plan of Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. have been met, although the stocks will not be listed immediately [1][10]. Group 1: Approval Process - The board of directors and the supervisory board approved the incentive plan and its related matters in multiple meetings held in March and May 2022 [6][7]. - The company conducted a public announcement of the list of incentive objects, which received no objections during the public notice period [6][7]. - The board and supervisory board held meetings in July 2022 to approve adjustments to the grant price and quantity of the restricted stocks [7]. Group 2: Vesting Conditions - The third vesting period for the restricted stocks is defined as the first trading day after 36 months from the grant date until the last trading day within 48 months from the grant date, allowing for a vesting ratio of 25% of the total granted stocks [11]. - The company’s 2024 revenue must increase by at least 60% compared to the 2021 revenue, which was approximately 7.44 billion yuan, to meet the performance conditions [13]. - A total of 336 incentive objects met the personal performance evaluation criteria, with 100% of them qualifying for the vesting [15]. Group 3: Stock Listing and Trading Restrictions - The vesting date for the restricted stocks is set for July 28, 2025, but the stocks will remain under a trading restriction for six months post-vesting [18]. - The company will apply for the listing of the vested stocks after the trading restriction period ends on January 27, 2026 [18]. Group 4: Independent Financial Advisor's Opinion - The independent financial advisor confirms that all conditions for the vesting of the restricted stocks have been satisfied and that the necessary approvals have been obtained, ensuring compliance with relevant laws and regulations [19].

北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 二〇二五年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭 州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 目 录 北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 第四个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 致：康龙化成（北京）新药技术股份有限公司 根据康龙化成（北京）新药技术股份有限公司（以下简称"康龙化成"、 "公 司"）与北京市中伦律师 ...

Core Viewpoint - The legal opinion letter from Zhong Lun Law Firm confirms that the adjustments and cancellations related to the 2023 A-share restricted stock incentive plan of Kanglong Chemical (Beijing) Co., Ltd. have received the necessary approvals and comply with relevant laws and regulations [2][9]. Summary by Sections Legal Opinion Overview - The legal opinion was issued based on a service contract between Kanglong Chemical and Zhong Lun Law Firm, with the firm acting as legal counsel for the 2023 A-share restricted stock incentive plan [3][7]. - The lawyers reviewed various documents related to the incentive plan and verified facts through public information from government departments [3][9]. Approval and Authorization - The adjustments and cancellations of the incentive plan have been approved by the company's board and shareholders, including the independent directors who provided their opinions [8][9]. - The company has authorized the board to manage and adjust the incentive plan as per the resolutions passed in the shareholder meetings [9]. Specifics of Adjustments - The adjustment of the grant price for the incentive plan was made following the completion of the company's 2024 annual equity distribution, with a cash dividend of 2 yuan per 10 shares declared [9]. - The adjusted grant price is in accordance with the relevant regulations and the incentive plan [9]. Specifics of Cancellations - A total of 634,880 shares of restricted stock that were granted but not vested have been canceled due to the failure to meet performance targets and the disqualification of certain incentive recipients [11]. - The cancellation aligns with the provisions of the incentive plan and relevant regulations [11].

Core Points - The establishment of the Compensation and Assessment Committee aims to enhance the management of compensation and assessment for directors and senior management, improving corporate governance structure [1] - The committee is responsible for formulating, managing, and assessing the compensation system for directors and senior management, reporting to the board of directors [1][2] - The committee consists of three directors, with the chairperson being an independent director [2] Group 1: Committee Structure - The committee is composed of three directors, nominated by the chairman, independent directors, or a third of all directors, and elected by the board [2] - The term of the committee aligns with that of the board, and if a member ceases to be a director, they automatically lose their committee position [2][3] - The committee can appoint a convenor from among its members, who is responsible for leading the committee's work [2] Group 2: Responsibilities and Authority - The committee's main responsibilities include formulating compensation plans for directors and senior management, reviewing their performance, and developing equity incentive plans [3][4] - The committee must submit its compensation plans and equity incentive proposals to the board for approval before implementation [4] - The committee can hire external agencies for professional advice, with costs borne by the company [4] Group 3: Meeting Procedures - The committee is required to hold at least one meeting annually, with provisions for additional meetings as needed [5] - Meetings can be convened by the convenor or at the request of the chairman, general manager, or two or more committee members [5] - A quorum for meetings requires the presence of more than half of the committee members, and decisions are made by a majority vote [5][6] Group 4: Documentation and Confidentiality - Meeting minutes must be recorded and signed by attendees, with members having the right to request their statements be included [7] - Members are obligated to maintain confidentiality regarding company information that has not been publicly disclosed [7]

Core Viewpoint - The announcement details the results of the second vesting period of the 2023 restricted stock incentive plan and the first vesting period of the 2024 plan, including the number of shares vested and the upcoming listing date for these shares [1][2][13]. Summary by Sections 1. Stock Listing and Vesting Details - The total number of shares to be listed for trading is 5,442,675 shares, with the listing date set for August 26, 2025 [1][13]. - The shares are part of the equity incentive program, with 3,567,870 shares from the 2023 plan and 1,140,000 shares from the 2024 plan [2][10]. 2. Vesting Quantity and Source - The 2023 plan's second vesting period includes 3,567,870 shares, while the 2024 plan's first vesting period includes 1,140,000 shares and 734,805 shares from the reserved grants [2][10]. - All shares are sourced from the company's directed issuance of A-share common stock to incentive targets [10][12]. 3. Decision-Making Process - The decision-making process for the vesting of shares involved multiple meetings and approvals from the board and supervisory committee, ensuring compliance with regulations and internal governance [3][5][6]. - Independent directors provided opinions on the benefits of the incentive plans for the company's sustainable development [3][5]. 4. Impact on Share Capital - Following the vesting, the company's total share capital will increase from 461,265,626 shares to 466,708,301 shares, without changing the controlling shareholder [13][15]. - The new shares will affect the earnings per share, diluting the basic earnings per share to -0.51 yuan per share based on the latest financial report [16]. 5. Compliance and Reporting - The company has completed the necessary registration procedures for the shares, as confirmed by the China Securities Depository and Clearing Corporation [2][15]. - A self-inspection report regarding insider trading was disclosed, ensuring transparency in the stock trading activities of insiders [4][7].

Summary of Key Points Core Viewpoint The company, Hefei Qizhong Technology Co., Ltd., has proposed a second revised draft of its 2024 Restricted Stock Incentive Plan, aiming to enhance corporate governance and attract key talent through a stock incentive mechanism. Group 1: Incentive Plan Overview - The total number of restricted stocks to be granted is 35.671119 million shares, accounting for approximately 3.00% of the company's total share capital as of the announcement date [2][4] - The initial grant consists of 34.950985 million shares, representing about 2.94% of the total share capital, while 720134 shares are reserved, making up 0.06% of the total [2][4] Group 2: Purpose of the Incentive Plan - The plan aims to improve the company's governance structure, establish a long-term incentive mechanism, and align the interests of shareholders, the company, and the core team [2][3] Group 3: Incentive Mechanism and Stock Source - The incentive method involves the issuance of second-class restricted stocks [3][4] - The stocks will be sourced from the company's directed issuance of A-shares or repurchased shares from the secondary market [3][4] Group 4: Granting and Vesting Conditions - The initial grant of restricted stocks is subject to performance conditions, including achieving specific financial metrics such as earnings per share and revenue growth rates [15][18] - The vesting period for the granted stocks is set for a maximum of 72 months, with specific vesting schedules outlined [9][12] Group 5: Performance Assessment - The performance assessment will be based on three key indicators: earnings per share, revenue growth rate, and net profit margin, with specific targets set for each assessment period [19][24] - The plan includes a detailed evaluation process for both company-level and individual performance [23][24] Group 6: Legal and Regulatory Compliance - The plan complies with relevant laws and regulations, including the Company Law and Securities Law, ensuring that the incentive mechanism is legally sound [3][15] - The company will conduct necessary disclosures and obtain approvals from the board and shareholders before implementation [25][26]

优利德科技（中国）股份有限公司 董事会薪酬与考核委员会关于公司2024年限制性股 票激励计划相关事项的核查意见 （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 优利德科技（中国）股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》《上市公司股权激励管理办法》（以下简称"《管理办 法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 则》"）等相关法律、法规及规范性文件和《优利德科技（中国）股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，对公司《2024 年限制性 股票激励计划（草案）》（以下简称"本次激励计划"、"《激励计划（草 案）》"）预留授予激励对象名单（截至授予日）及首次授予部分限制性股票 第一个归属期的归属名单进行了核查，并发 ...

A 股代码：688428 A 股简称：诺诚健华 公告编号：2025-035 港股代码：09969 港股简称：诺诚健华 一、限制性股票授予情况 （一）本次限制性股票授予已履行的决策程序和信息披露情况 诺诚健华医药有限公司 关于向激励对象授予预留限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 限制性股票预留授予日：2025 年 8 月 20 日 ? 限制性股票预留授予数量：246.7550 万股，约占目前公司已发行股份总数 ? 股权激励方式：第二类限制性股票 诺诚健华医药有限公司（以下简称"诺诚健华"或"公司"）《2024 年科创 板限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"）规定 的公司 2024 年科创板限制性股票激励计划（以下简称"本次激励计划"或"本激 励计划"）的预留授予条件已经成就，根据公司 2024 年第一次临时股东大会（股 东特别大会）的授权，公司于 2025 年 8 月 20 日召开董事会审议通过了《根据 2024 年科创板限制性股票激励计划向激励对象 ...

北京三元食品股份有限公司 关于调整限制性股票回购价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次调整前，首次授予限制性股票回购价格为 3.002 元/股。 ? 鉴于公司 2023 年度、2024 年度利润分配方案已实施完毕，每股分别派 发现金红利 0.049 元（含税）、0.012 元（含税），故需对限制性股票回购价格进 行相应调整。本次调整后，首次授予限制性股票回购价格为 2.941 元/股。 北京三元食品股份有限公司（简称"公司"）于 2025 年 8 月 19 日召开了 第九届董事会第三次会议、第八届监事会第十五次会议，审议并通过了《关于 调整限制性股票回购价格的议案》，具体情况如下： 股票代码：600429 股票简称：三元股份 公告编号：2025-031 一、股权激励计划已履行的决策程序和信息披露情况 会第十三次会议审议通过了《关于公司 2022 年限制性股票激励计划（草案） 及其摘要的议案》《关于公司 2022 年限制性股票授予方案的议案》《关于公司 的相关议案发表了独立意见，监事 ...

Core Viewpoint - The company plans to repurchase and cancel a total of 7.086978 million restricted shares due to unmet performance targets and changes in the status of certain incentive recipients [1][8][10] Group 1: Repurchase Details - The number of restricted shares to be repurchased is 7.086978 million [1] - The repurchase price for some shares is determined by the lower of the adjusted grant price of 2.941 yuan per share or the market price [1][8] - The repurchase involves 167 incentive recipients, with 580.9317 million shares linked to unmet performance targets, and additional shares from 11 recipients due to retirement or job changes, totaling 72.3331 million shares, and 12 recipients due to resignation, totaling 55.4330 million shares [2][8][9] Group 2: Performance and Compliance - The second unlock period's performance assessment targets were not fully met, leading to the proposed repurchase [2][9] - The repurchase is in accordance with the company's stock incentive plan and relevant regulations [10][12] - The company will use its own funds for the repurchase [9] Group 3: Impact on Share Capital - After the repurchase, the total share capital will decrease from 1,509,176,043 shares to 1,502,089,065 shares [10] - The repurchased shares represent approximately 0.47% of the company's current total share capital [8] Group 4: Legal and Regulatory Compliance - The company has obtained necessary approvals and authorizations for the repurchase and cancellation of shares [12] - The legal opinion confirms that the repurchase aligns with the management regulations and the stock incentive plan [12]